MegaPro Biomedical Co EV/EBIT
The EV/EBIT (Enterprise Value to EBIT) of MegaPro Biomedical Co (6827.TWO) as of Aug 1, 2026 is -7.84. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -5.20 — a change of 50.68% (lower).
Get this data via API
Financial Data API
EV/EBIT
-7.84
YoY
50.68%
Last updated:
EV/EBIT (Enterprise Value to EBIT) of MegaPro Biomedical Co is 2026 -7.84 . EV/EBIT (Enterprise Value to EBIT) of MegaPro Biomedical Co was 2025 -5.20 . It decreases by 50.68% lower compared to the previous year.
The MegaPro Biomedical Co EV/EBIT history
3 Years
10 Years
25 Years
Max
PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2018
0.00 base
Jan 1, 2019
0.00 base
Jan 1, 2020
0.00 base
Jan 1, 2021
-16.71 base
Jan 1, 2022
-9.50 base
Jan 1, 2023
-10.55 base
Jan 1, 2024
-5.23 base
Jan 1, 2025
-7.06 base
| YEAR | PRICE-TO-EBIT |
|---|---|
| 2025 | -7.06 |
| 2024 | -5.23 |
| 2023 | -10.55 |
| 2022 | -9.50 |
| 2021 | -16.71 |
| 2020 | - |
| 2019 | - |
| 2018 | - |
Access this data via the Eulerpool API
MegaPro Biomedical Co Stock analysis
What does MegaPro Biomedical Co do? MegaPro Biomedical Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about MegaPro Biomedical Co stock
EV/EBIT (Enterprise Value to EBIT) of MegaPro Biomedical Co is -7.84 in 2026.
Access this data via the Eulerpool API
Valuation — MegaPro Biomedical Co
All Key Metrics — MegaPro Biomedical Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth